Charles River Laboratories International, Inc. (NYSE:CRL – Get Free Report) EVP Victoria Creamer sold 4,179 shares of the stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $259.16, for a total transaction of $1,083,029.64. Following the completion of the sale, the executive vice president owned 30,051 shares of the company’s stock, valued at approximately $7,788,017.16. This represents a 12.21% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Charles River Laboratories International Stock Up 1.1%
Charles River Laboratories International stock opened at $284.99 on Thursday. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.35 and a quick ratio of 1.04. The company’s 50-day moving average is $220.98 and its 200-day moving average is $190.27. The firm has a market capitalization of $13.61 billion, a PE ratio of -58.76, a P/E/G ratio of 2.92 and a beta of 1.38. Charles River Laboratories International, Inc. has a fifty-two week low of $144.26 and a fifty-two week high of $288.02.
Charles River Laboratories International (NYSE:CRL – Get Free Report) last issued its earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.25. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The business had revenue of $1 billion during the quarter, compared to the consensus estimate of $980.53 million. During the same period last year, the business posted $3.12 EPS. Charles River Laboratories International’s revenue was down 2.7% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. Sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 11.35 earnings per share for the current year.
Charles River Laboratories International News Roundup
- Positive Sentiment: Earnings exceeded expectations. Charles River reported fiscal second-quarter adjusted earnings of $3.02 per share, above the $2.77 analyst consensus, while revenue of approximately $1.0 billion also topped expectations of $980.5 million. Management maintained fiscal 2026 earnings guidance of $11.15 to $11.45 per share. Charles River Laboratories Q2 2026 Earnings Call Transcript
- Positive Sentiment: Analyst sentiment remains supportive. Piper Sandler and Barclays set or maintained $300 price targets, while RBC raised its target to $282 and reiterated an outperform rating. JPMorgan also upgraded CRL to overweight with a $310 target. The overall analyst consensus is “Moderate Buy,” with 12 Buy ratings, three Holds and one Sell. Charles River Laboratories Consensus Rating
- Positive Sentiment: Investor focus remains on management’s outlook. Articles reviewing the second-quarter earnings call highlighted analyst questions about Charles River’s operating trends and forward expectations. The discussion helps investors assess whether the earnings beat and 2026 guidance can be sustained. Analyst Questions From Charles River’s Q2 Earnings Call
- Positive Sentiment: Technical momentum is strong. CRL reached a new 52-week high near $277, with trading volume above its average. Shares remain substantially above their 50-day and 200-day moving averages, reinforcing bullish momentum. Charles River Laboratories Sets New 52-Week High
- Negative Sentiment: Multiple insiders sold shares. Director James C. Foster sold 28,733 shares for approximately $7.9 million under a pre-arranged Rule 10b5-1 plan, reducing his holdings by 47.6%. EVP Victoria Creamer separately sold 4,179 shares worth about $1.1 million. The planned transactions may weigh on sentiment, although they do not necessarily indicate weakening business prospects. SEC Insider Transaction Filing
Institutional Investors Weigh In On Charles River Laboratories International
A number of institutional investors have recently modified their holdings of the business. Los Angeles Capital Management LLC bought a new position in Charles River Laboratories International during the fourth quarter worth about $42,000. Sfam LLC bought a new stake in Charles River Laboratories International in the 4th quarter valued at about $43,000. Activest Wealth Management boosted its holdings in Charles River Laboratories International by 10,900.0% in the 4th quarter. Activest Wealth Management now owns 220 shares of the medical research company’s stock valued at $44,000 after purchasing an additional 218 shares during the period. Geneos Wealth Management Inc. grew its position in shares of Charles River Laboratories International by 98.0% during the 2nd quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock worth $44,000 after purchasing an additional 145 shares in the last quarter. Finally, Elyxium Wealth LLC bought a new position in shares of Charles River Laboratories International during the fourth quarter worth approximately $46,000. Institutional investors own 98.91% of the company’s stock.
Analyst Upgrades and Downgrades
Several research analysts have recently commented on CRL shares. Mizuho set a $264.00 target price on Charles River Laboratories International in a research note on Monday. TD Cowen lifted their price objective on shares of Charles River Laboratories International from $235.00 to $300.00 and gave the stock a “buy” rating in a research report on Monday. JPMorgan Chase & Co. upgraded shares of Charles River Laboratories International from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $180.00 to $310.00 in a report on Thursday, August 6th. CLSA lowered shares of Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 price objective on the stock. in a research report on Monday, July 20th. Finally, Sanford C. Bernstein set a $250.00 target price on shares of Charles River Laboratories International in a research note on Wednesday, July 1st. Twelve analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $255.65.
View Our Latest Stock Report on CRL
About Charles River Laboratories International
Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.
Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.
Featured Articles
- Five stocks we like better than Charles River Laboratories International
- GE Vernova’s AI Power Boom Faces a Profit Test
- Cardinal Health Earnings: Can Perfection Get Priced In Twice?
- Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand
- Legacy Jet Builders Stall While Embraer Accelerates to New Highs
Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.
